Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7745731 | 0.86 | TSHR (0.50) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL5109530 | 0.85 | AGTR1 (0.48) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL6244917 | 0.84 | TSHR (0.50) | TSHRMAPK1CNR2BCHEACHE | |
| Bromide SCHEMBL5929370 | 0.83 | AGTR1 (0.47) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL13041648 | 0.82 | TSHR (0.48) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL3732116 | 0.81 | ALOX5AP (0.48) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL3729168 | 0.80 | TSHR (0.76) | TSHRMAPK1 | |
| SCHEMBL2876339 | 0.80 | CNR2 (0.49) | TSHRMAPK1CNR2BCHEACHE | |
| SCHEMBL15908540 | 0.80 | AGTR1 (0.41) | TBXA2RAGTR1AGTR2 | |
| Hydrochloric Acid SCHEMBL16163295 | 0.79 | TSHR (0.74) | TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |